On Tuesday, Following U.S. Stocks were among the “Top Gainers”:Urban Outfitters, (NASDAQ:URBN), Cytori Therapeutics, (NASDAQ:CYTX), Opexa Therapeutics, (NASDAQ:OPXA)
- Urban Outfitters, (NASDAQ:URBN), with shares inclined 11.52%, closed at $44.06, hitting new 52-week high of $44.20.
- Cytori Therapeutics, (NASDAQ:CYTX), with shares jumped 8.87%, settled at $1.35.
- Opexa Therapeutics, (NASDAQ:OPXA), with shares climbed 7.94%, and closed at $0.82.
Latest NEWS regarding these Stocks are depicted underneath:
Urban Outfitters Inc. (NASDAQ:URBN):
Urban Outfitters Inc. (URBN), a leading lifestyle specialty retail corporation operating under the Anthropologie, Bhldn, Free People, Terrain and Urban Outfitters brands, declared net revenue of $80 million and $232 million for the three months and year ended January 31, 2015, respectively. Earnings per diluted share were $0.60 and $1.68 for the three months and year ended January 31, 2015, respectively.
Total Corporation net sales for the fourth quarter of fiscal 2015 raised 12% over the same quarter last year to a record $1.01 billion. Comparable Retail segment net sales, which comprise our comparable direct-to-consumer channel, raised 6%. Comparable Retail segment net sales raised 18% at Free People, 6% at the Anthropologie Group and 4% at Urban Outfitters. Wholesale segment net sales rose 21%.
For the year ended January 31, 2015, total Corporation net sales raised 8% over the preceding year to a record $3.3 billion. Comparable Retail segment net sales raised 2%. Wholesale segment net sales raised 27%.
For the three months ended January 31, 2015, the gross profit rate reduced by 207 basis points as compared to the preceding year`s comparable period. The deleverage occurred primarily due to lower initial merchandise markups followed by higher markdowns, which were primarily driven by the underperformance at the Urban Outfitters brand. For the year ended January 31, 2015, the gross profit rate reduced by 227 basis points as compared to the preceding year`s comparable period. The deleverage occurred primarily due to lower initial merchandise markups, store occupancy deleverage due to negative store comparable net sales and higher markdowns, which were primarily driven by the underperformance at the Urban Outfitters brand.
As of January 31, 2015, total inventories raised by $47 million, or 15%, on a year-over-year basis. The growth in total inventories is primarily related to the attainment of inventory to stock new and non-comparable stores in addition to an raise in comparable Retail segment inventories. Comparable Retail segment inventories raised 7% at cost while decreasing 7% in units.
For the three months ended January 31, 2015, selling, general and administrative expenses, expressed as a percentage of net sales, leveraged by 8 basis points when contrast to the preceding year period. For the year ended January 31, 2015, selling, general and administrative expenses, expressed as a percentage of net sales, deleveraged by 56 basis points contrast to the preceding year period primarily due to raised marketing and technology expenses which were used to drive higher direct-to-consumer traffic.
The Corporation`s effective tax rate for the fourth quarter of fiscal 2015 was 35.0% contrast to 31.7% in the preceding year period. The tax rate variance is due to preceding year favorable one-time benefits pertaining to a federal rehabilitation credit received related to the expansion of the Corporation`s home office and the release of foreign valuation allowances.
Urban Outfitters, Inc. is an innovative specialty retail corporation which offers a variety of lifestyle merchandise to highly defined customer niches through 238 Urban Outfitters stores in the United States, Canada, and Europe, catalogs and websites.
Cytori Therapeutics, Inc. (NASDAQ:CYTX)
Formerly on March 4, Cytori Therapeutics, Inc. (CYTX), offered a business and financial performance update in its presentation at the Cowen and Corporation 35th Annual Health Care Conference in Boston.
The corporate presentation comprises certain top-line preliminary unaudited financial results for the quarter and full year ended December 31, 2014 and select performance guidance for the full-year 2015.
- Preliminary cash and debt balances at December 31, 2014 of about $14.6 million and $25 million, respectively.
- Preliminary Q4 and full-year 2014 operating cash burn of about $4.9 million and $30.3 million; respectively.
- Preliminary Q4 and full-year 2014 product proceed of about $2.5 million and $5.0 million, respectively.
- Preliminary Q4 and full-year 2014 contribution (profit/loss) from our sales and marketing organization, not including share based compensation, of a profit of about $44 thousand and a loss of about $3.9 million, respectively.
- Preliminary Q4 and full-year 2014 contract proceed of about $1.3 million and $2.6 million, respectively.
- Estimation of 2015 operating cash burn of about $25 million.
- Full-year 2015 product proceed predictable to be within a range from $5 million and $8 million.
- Full-year 2015 contribution (profit/loss) from our sales and marketing organization, not including share based compensation, predictable to be a profit ranging from $100 thousand and $300 thousand.
- Full-year 2015 contract proceed predictable to be within a range from $6 million and $8 million.
Cytori Therapeutics, Inc., a cell therapy corporation, develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions.
Opexa Therapeutics, Inc. (NASDAQ:OPXA)
Opexa Therapeutics, Inc. (OPXA), a corporation developing personalized immunotherapies for autoimmune disorders, counting multiple sclerosis (MS) and neuromyelitis optica (NMO), provides shareholders a reminder of its rights offering and its calendar, as shareholders should ensure they own Opexa’s stock as of 4:00 PM ET on Tuesday, March 10, 2015 to be considered a shareholder of record on Friday, March 13, 2015.
The Corporation’s registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission (SEC) on Wednesday, February 25, 2015.
Opexa is a biopharmaceutical corporation developing a personalized immunotherapy with the potential to treat major illnesses, counting multiple sclerosis (MS) in addition to other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content described in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
